Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

RESULTS FROM A PHASE I/II CLINICAL STUDY OF SYS6043 (B7-H3 ADC) FOR THE TREATMENT OF ADVANCED BREAST CANCER PRESENTED AS A RAPID ORAL PRESENTATION AT THE ESMO CONGRESS 2026

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the results in patients with advanced breast cancer from a Phase I/II clinical study (the "**Study**") of SYS6043, a novel B7 homologue 3 ("**B7-H3**")-targeted antibody-drug conjugate ("**ADC**") independently developed by the Group, were presented as a rapid oral presentation (No.: 5RO) at the European Society for Medical Oncology ("**ESMO**") Congress 2026 on 26 October 2026. The Study was presented by Professor Wang Hongxia from Fudan University Shanghai Cancer Centre.

STUDY OVERVIEW

The Study is a multicentre, open-label Phase I/II clinical study jointly led by Professor Zhang Li of Sun Yat-sen University Cancer Centre and Professor Wu Lingying of Cancer Hospital, Chinese Academy of Medical Sciences, designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SYS6043 in patients with advanced solid tumours.

This presentation focused on the breast cancer cohort. As at the data cut-off date (15 June 2026), a total of 139 patients with advanced breast cancer were enrolled in this cohort, including hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer ("**HR+/HER2-BC**", n=84), triple-negative breast cancer ("**TNBC**", n=32), and HER2-positive (HER2+) breast cancer ("**HER2+BC**", n=23). The median age of the patients was 54 years, and the majority of patients had previously received multiple lines of therapy.

STUDY RESULTS

At this congress, the Group presented the positive results of the Study, with the relevant safety and efficacy data as follows:

Safety:

Among the 139 patients who received at least one dose of treatment, SYS6043 was generally well-tolerated. The incidence of treatment-related adverse events ("**TRAE**s") was 99.3%, the incidence of Grade≥3 TRAEs was 28.8%, and the incidence of serious TRAEs was 5.8%. The most common TRAEs included nausea (61.2%), leukopenia (60.4%), neutropenia (55.4%), anaemia (51.1%) and fatigue (51.1%). The proportions of patients experiencing dose interruption and dose reduction due to TRAEs were 24.5% and 6.5%, respectively, and only 1 patient (0.7%) discontinued treatment due to a TRAE. No treatment-related deaths occurred in the Study. The incidence of interstitial lung disease (ILD) was 1.4%.

Efficacy:

SYS6043 demonstrated positive anti-tumour activity in efficacy-evaluable patients across all three breast cancer subtypes:

- HR+/HER2-BC (n=82): After a median follow-up of 5.1 months, the confirmed objective response rate ("**ORR**") was 53.7%, the disease control rate ("**DCR**") was 92.7%, and the median duration of response ("**DoR**") and median progression-free survival ("**PFS**") were not reached;

- TNBC (n=32): After a median follow-up of 6.5 months, the confirmed ORR was 75.0%, the DCR was 93.8%, the median PFS was 7.2 months, and the median DoR was 5.5 months;

- HER2+BC (n=23): After a median follow-up of 6.4 months, the confirmed ORR was 69.6%, the DCR was 95.7%, the median PFS was not reached, and the median DoR was 7.0 months.

STUDY CONCLUSION

SYS6043 demonstrated a manageable safety profile and favourable durable anti-tumour activity in previously treated patients with advanced breast cancer, supporting further investigation at a dose of 6 mg/kg once every three weeks (Q3W).

ABOUT SYS6043

SYS6043 is an ADC independently developed by the Group targeting B7-H3, with a topoisomerase I inhibitor as its payload. It has a drug-to-antibody ratio (DAR) of approximately 6. SYS6043 adopts a crystallisable fragment γ (Fc γ) receptor effector function-silencing design and a cleavable linker, featuring a bystander anti-tumour effect, with the aim of enhancing anti-tumour activity and reducing off-target toxicity. B7-H3 is highly expressed in various solid tumours and has a high expression frequency in breast cancer, making it a therapeutic target with promising clinical application prospects.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 27 October 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.